Get started
Author

G. Raab

Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxel Every 14 Days As Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast Group
2005 · Gunter von Minckwitz, Günter Raab, et al. · Journal of Clinical Oncology · 415
PDF
Dose-Dense Doxorubicin, Docetaxel, and Granulocyte Colony-Stimulating Factor Support With or Without Tamoxifen as Preoperative Therapy in Patients With Operable Carcinoma of the Breast: A Randomized, Controlled, Open Phase IIb Study
2001 · Gunter von Minckwitz, Serban D. Costa, et al. · Journal of Clinical Oncology · 145
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast
2008 · Gunter von Minckwitz, Hans-Peter Sinn, et al. · Breast Cancer Research · 123
PDF
Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.
2003 · Giulia Bianchi, John Albanell, et al. · PubMed · 54
Response of human endometrium and ovarian carcinoma cell-lines to photodynamic therapy
1990 · G. H. Raab, A. F. Schneider, et al. · Archives of Gynecology and Obstetrics · 25
Primary endpoint analysis of the GEPARDUO study: Comparing dose-dense with sequential adriamycin/docetaxel combination as preoperative chemotherapy (PCHT) in operable breast cancer (T2-3, N0-2, M0)
2003 · A. Loehr, G. von Minckwitz, et al. · The Breast · 22
The effect of tamoxifen and stilboestrol on plasma hormone levels in postmenopausal women with advanced breast cancer.
1979 · I J McFadyen, G Raab, et al. · PubMed · 17
Clinical response by palpation during primary systemic therapy with four dose-dense cycles doxorubicin and docetaxel in patients with operable breast cancer: Further results from a randomised controlled trial
2007 · Christine Müller, Angelika Caputo, et al. · European Journal of Cancer · 9
Maintenance of Dose Intensity in Adjuvant Chemotherapy of Breast Cancer in Patients Treated Outside a Clinical Trial - Results of a Retrospective Study
2003 · C. Jackisch, M. Jaber, et al. · Geburtshilfe und Frauenheilkunde · 6
Entwicklung und Integration des Onkologischen Dokumentationssystems ODS
2001 · G. Raab, M. van den Bergh · Zentralblatt für Gynäkologie · 6
TAC as neoadjuvant chemotherapy in patients with primary breast cancer - interim progress report on 907 cases of the randomized prospective Gepartrio-trial
2004 · S. Costa, G. Von Minckwitz, et al. · Journal of Clinical Oncology · 5
Präoperative Chemotherapie operabler primärer Mammakarzinome mit einer dosisdichten Kombination von Adriamycin und Docetaxel (ADoc) - Die Erfahrungen der GEPARDO-GABG-Studiengruppe -
2001 · G. von Minckwitz, G. Raab, et al. · Zentralblatt für Gynäkologie · 5
An eight weeks dose-dense versus a 24 weeks sequential adriamcycin/docetaxel combination as preoperative chemotherapy (CHT) in operable breast cancer (T2-3, N0-2,M0)
2001 · G. von Minckwitz, G. Raab, et al. · European Journal of Cancer · 4
Chromogen in situ hybridisation (CISH) for HER2 assessment is highly concordant with FISH in core cut biopsies of primary T2 breast cancers
2004 · G. H. Raab, B. Hoegel, et al. · Journal of Clinical Oncology · 3
Effectiveness of Vinorelbine/Capecitabine (NX) versus Docetaxel/Doxorubicin/Cyclophosphamide (TAC) in patients non-responding to 2 cycles of neoadjuvant TAC chemotherapy: First Results of the phase III GEPARTRIO-Study by the German Breast Group
2006 · B. Gerber, G. von Minckwitz, et al. · European Journal of Cancer Supplements · 2
An open label, randomized phase II trial of primary systemic therapy with exemestane (EXE 25 mg/d) plus epirubicin (EPI, 20 vs 30 mg/m 2 q1w × 8–12) in breast cancer: An interim analysis of the German Neoadjuvant Aromasin Initiative (GENARI-3)
2004 · C. J. Wolf, G. Raab, et al. · Journal of Clinical Oncology · 2
Trastuzumab, ein neuer Behandlungsansatz beim Mammakarzinom
2001 · G. Raab, W. Eiermann · Der Internist · 2
Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy in early breast cancer (EBC) – a German health economic analysis.
2009 · MP Lux, A Benedict, et al. · Cancer Research · 1
The effect of chemotherapy on pituitary function in patients with advanced breast cancer.
1979 · I J McFadyen, G Raab, et al. · PubMed · 1
Erarbeitung von BVT-Merkblättern und deren zukünftige Verbindlichkeit
2011 · G. Raab · I + E
Anastrozol – eine kostennutzwerte Option in der endokrinen adjuvanten Therapie von Patientinnen mit einem hormonrezeptorpositiven Mammakarzinom. Ergebnisse des Arimidex®-Gesundheitsökonomiemodells für das deutsche Gesundheitssystem unter Berücksichtigung nationaler und internationaler Standards
2008 · MP Lux, A Wöckel, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
Fulvestrant, eine kostennutzwerte Option in den unterschiedlichen Therapieszenarien der palliativen Situation – Ergebnisse des Faslodex® Gesundheitsökonomiemodells
2008 · MP Lux, M Hartmann, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
Fulvestrant, eine kostennutzwerte Option in der palliativen Situation. – Ergebnisse des German Faslodex® health economic sequencing model
2008 · MP Lux, N Harbeck, et al. · Geburtshilfe und Frauenheilkunde
Docetaxel/Doxorubicin/Cyclophosphamid (TAC) versus Vinorelbin/Capecitabin (NX) bei Patienten, die nach 2 Zyklen neoadjuvanter Chemotherapie mit TAC kein Ansprechen zeigen – erste Studienergebnisse der GEPARTRIO-Studie der German Breast Group (GBG)
2006 · G von Minckwitz, S Kümmel, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
P42 Prevention of breast cancer: Results of a survey towards attitudes of women with an average risk of breast cancer (n = 7000) and gynaecologists (n = 800) in Germany
2004 · S. Paepke, U. Schwarz-Boeger, et al. · European Journal of Cancer Supplements
Works count: 31
Citation count: 847
H-index: 8
I10-index: 7
Year
Topic
Type